Navigation Links
VG Life Sciences Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial

SAN MARINO, Calif., April 4, 2013 /PRNewswire/ -- VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today positive results from stage two of its Pre-IND Phase I Study to test tolerability and toxicity in patients with advanced stage solid tumors.  The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), developed with VGLS' proprietary metabolic disruption technology (MDT), in combination with sorafenib (marketed as Nexavar®), which was co-developed by Bayer AG and Onyx Pharmaceuticals.

Haig Keledjian , CEO of VG Life Sciences, said, "We are happy to report we attained the safety endpoints we anticipated for our second cohort of patients.  Similar to the positive results we announced previously for our first patient cohort, no significant toxicities were observed at a higher dose of HCQ in combination with sorafenib.  We have begun enrolling patients into the next dosing cohort in this dose-escalation study and look forward to reporting those results in a timely fashion.  We anticipate patient recruitment to accelerate since opening up the enrollment criteria to include patients with breast, colon, lung, liver, pancreatic, and ovarian cancer, and look forward to an ultimate study completion date, from a safety standpoint, of third quarter 2013."

Dr. Tyler Curiel , gynecological oncologist at the Cancer Therapy & Research Center in San Antonio, TX, and principal investigator for the trial said, "Having successfully finished enrollment in cohort two, we have begun treating patients in the third cohort. The safety of our patients is paramount and these results give us the needed information so that we can continue advancing in this next cohort.  The purpose of this study is to establish the safety profile and determine appropriate doses of this combination of anti-cancer drugs."

The trial is supported by a donation from the Scott and White Foundation.  

Details on the Phase 1 study protocol can be downloaded from VG Life Sciences' website and viewed here.  Additional information on the trial can be found at

About VG Life Sciences, Inc.
Founded in 1994, San Marino, California-based VG Life Sciences, Inc. is a biotech company researching treatments for drug-resistant cancer, Lyme disease, Strep, Staph and Sepsis, and HIV/AIDS.  The company's current drug candidates are based on two exclusively licensed platform technologies: Metabolic Disruption (MDT) and Targeted Peptides (TPT); and are covered by the company's portfolio of more than 60 patents.  A physician-initiated Phase I clinical trial of VG Life Sciences' MDT compound in combination with Nexavar™ is ongoing at the Cancer Therapy and Research Center of The University of Texas Health Science Center at San Antonio in patients with refractory or relapsed solid tumors. For more information, visit

A majority-owned subsidiary, VG Energy (, is dedicated to exploring biofuel and agricultural applications for the MDT platform.  

Safe Harbor Statement and Forward-Looking Statements

This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences or any other person that the objectives and plans of VG Life Sciences will be achieved.

VG Life Sciences Contact:
Haig Keledjian , Founder, CEO & President

For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm , Ph.D. / Andrew Mielach; 212-375-2664; 212-375-2694


SOURCE VG Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
2. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
3. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
4. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
5. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
6. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
7. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
8. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
9. PointCross Life Sciences SENDBox and SEND-as-a-Service Prepare Pharma Companies to Comply with the FDAs Upcoming e-Data Submission Mandate
10. For International Life Sciences, Biotech and Pharmaceutical Events, Top Executives Turn to Global Information
11. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
Post Your Comments:
(Date:10/13/2015)... 2015  Nanomedical Diagnostics, a biotech company developing ... diagnostics, announces the completion of a Series A ... Ventures. --> ... monitoring and diagnostic platforms that empower individuals to ... will enable the company to commercially release AGILE ...
(Date:10/13/2015)... Oct. 9, 2015 Research and Markets ( ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), Flavors ... Flowers, Others), & by Region - Forecasts to 2020" ... --> --> The global ... few years. In terms of value, the market is ...
(Date:10/13/2015)... Oct. 13, 2015   Micell Technologies , Inc. ... and II trials of its MiStent Sirolimus Eluting Absorbable ... ) were presented at the 27th Annual Transcatheter Cardiovascular ... San Francisco , October 11-15. TCT is the ... MiStent SES was designed to optimize vessel healing in ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University announced Tuesday (Oct. ... Initiative aimed at enhancing Purdue’s life sciences research and graduate education. The initiative ... , The investment will result in cohesive efforts across several colleges and is ...
(Date:10/13/2015)... ... 13, 2015 , ... "My friend's son suffers from eczema, and he had ... an inventor from Platteville, Colo. "I came up with this kit as a way ... to prevent a child from rubbing or scratching his or her face. This protects ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ProText Kinetic ... X . With ProText Kinetic Panel, users can create energetic text animations in any ... preset into the Final Cut Pro X timeline and stylize the text. With intuitive ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology ... today a significant contract that will provide its award-winning private messaging solution to ... the growing success of its Relay program, IBX Wire™, which now has over ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading Internet marketing product review ... "Publish Academy" training course . Singal's new program, in which he reveals his ... around the Internet are weighing in with reviews. , "Considering the fairly high ...
Breaking Medicine News(10 mins):